Gilead Sciences, Inc. (GILD)
Gilead Sciences, Inc. reported revenue of $29.44B for the fiscal year ended Dec 31, 2025, up 2.4% from $28.75B the year before. Net income was $8.51B, a net margin of 28.9% (prior year: $480.00M). At the end of that fiscal year the company reported total assets of $59.02B and shareholders' equity of $22.70B.
Revenue
$29.44B
+2.4% vs prior year
Net income
$8.51B
Net margin 28.9%
Diluted EPS
$6.78
USD per share
Total assets
$59.02B
At Dec 31, 2025
Equity
$22.70B
At Dec 31, 2025
Shares outstanding
1,240M
As of Oct 23, 2026
Explore Gilead Sciences, Inc.'s filings
- Revenue by year — annual and quarterly revenue with growth rates
- Income statement & cash flow — profit, margins, EPS and operating cash flow
- Balance sheet — assets, liabilities, equity, cash and debt
- SEC filings — 10-K and 10-Q filings with links to EDGAR
Latest SEC filings
- 10-QFiled Oct 30, 2026
- 10-QFiled Aug 6, 2026
- 10-QFiled May 7, 2026
- 10-KFiled Feb 24, 2026
- 10-QFiled Nov 7, 2025
- 10-QFiled Aug 7, 2025
Source: SEC EDGAR XBRL company facts for CIK 882095 (raw data). Most recent filing in this dataset: 10-Q filed Oct 30, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.